Literature DB >> 15118534

Structure and functions of the endothelial cell protein C receptor.

Charles T Esmon1.   

Abstract

The endothelial cell protein C receptor (EPCR) plays a critical role in augmenting protein C activation by the thrombin-thrombomodulin complex and in modulating the functions of the protein C pathway to aid in preventing organ damage due to various challenges. EPCR exhibits a sequence and three-dimensional homology with the major histocompatibility class 1/CD1 family of proteins. This family of proteins is characterized by having a deep groove that is usually used in antigen presentation. In the case of CD1c and CD1d, this groove is filled with a lipid antigen, usually a glycolipid. Like the CD1 series, EPCR has a lipid in the corresponding groove. In this case, the lipid is usually phosphatidylcholine, but it may be phosphatidylethanolamine. The bound lipid contributes to protein C binding, but its structure suggests a role in maintaining EPCR structure rather than contributing directly to protein C binding. Potential roles for EPCR in hematopoiesis are suggested by the finding that EPCR is located on hematopoietic stem cells at reasonably high concentrations. The structure and the lipid antigen suggest that EPCR may be involved in preventing autoimmunity, which would be consistent with findings in CD1d knockout mice. Complete deletion of EPCR function results in embryonic death, at least in part due to placental thrombosis. In adult animals, the anticoagulant and anti-inflammatory responses to endotoxin increase with increasing EPCR expression. Some of the anti-inflammatory activity is likely to be due to EPCR's interactions with the integrin Mac-1 (CD11b/CD18) on leukocytes, an interaction that probably limits tight adhesion of leukocytes to activated endothelium. Thus, available data suggest a potential role of EPCR in hematopoiesis, autoimmunity, and the control of both the coagulation and inflammation responses to infection and trauma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118534     DOI: 10.1097/01.ccm.0000126128.64614.81

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  30 in total

1.  Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Authors:  Michael Nebozhyn; Andrey Loboda; Laszlo Kari; Alain H Rook; Eric C Vonderheid; Stuart Lessin; Carole Berger; Richard Edelson; Calen Nichols; Malik Yousef; Lalitha Gudipati; Meiling Shang; Michael K Showe; Louise C Showe
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

2.  Piperlonguminine downregulates endothelial protein C receptor shedding in vitro and in vivo.

Authors:  Sae-Kwang Ku; Jeong Ah Kim; Jong-Sup Bae
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

3.  Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) mice.

Authors:  Meilang Xue; Suat Dervish; Leonard C Harrison; Gregory Fulcher; Christopher J Jackson
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

Review 4.  Endothelial cell protein C receptor: a multiliganded and multifunctional receptor.

Authors:  L Vijaya Mohan Rao; Charles T Esmon; Usha R Pendurthi
Journal:  Blood       Date:  2014-07-21       Impact factor: 22.113

Review 5.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 6.  Thrombin generation in hemorrhage control and vascular occlusion.

Authors:  Kenneth G Mann
Journal:  Circulation       Date:  2011-07-12       Impact factor: 29.690

7.  Soluble thrombomodulin protects ischemic kidneys.

Authors:  Asif A Sharfuddin; Ruben M Sandoval; David T Berg; Grant E McDougal; Silvia B Campos; Carrie L Phillips; Bryan E Jones; Akanksha Gupta; Brian W Grinnell; Bruce A Molitoris
Journal:  J Am Soc Nephrol       Date:  2009-01-28       Impact factor: 10.121

8.  EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; Charles T Esmon; L Vijaya Mohan Rao
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

Review 9.  Factor VIIa binding to endothelial cell protein C receptor.

Authors:  L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  Thromb Res       Date:  2008       Impact factor: 3.944

10.  Alternative mRNA is favored by the A3 haplotype of the EPCR gene PROCR and generates a novel soluble form of EPCR in plasma.

Authors:  Beatrice Saposnik; Elodie Lesteven; Anna Lokajczyk; Charles T Esmon; Martine Aiach; Sophie Gandrille
Journal:  Blood       Date:  2007-12-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.